Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
ABSTRACT: 16
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase?III BREAKWATER trial led by researchers at Â鶹ӳ» MD Anderson Cancer Center.
The findings, presented today at the American Society of Clinical Oncology...
MD Anderson Research Highlights for January 22, 2025
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
ExxonMobil donates $10 million to fund MD Anderson-led Be Well? Beaumont initiative
In an effort to improve public health and reduce cancer risk in East Texas, leaders in Beaumont are working with?Â鶹ӳ»...
Chances of quitting smoking improve with integrated care, including medication and counseling
Smokers undergoing lung cancer screening may have the best chance of quitting if they receive integrated care, which includes medication and comprehensive counseling with tobacco treatment specialists, according to researchers at Â鶹ӳ» MD?Anderson Cancer Center.
The study results, published today in JAMA Internal Medicine, demonstrated that integrated care outperformed other cessation methods with a nearly...
MD Anderson Research Highlights for January 9, 2025
Â鶹ӳ» MD Anderson Cancer Center¡¯s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad¡¯s molecular residual disease assay
Â鶹ӳ» MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the...